|  Find a Doctor   |  Getting to NUHCS   | Appointment   | Contact Us   | Newsroom  |  Make a Gift  | About NUHS  | Protecting Your Data

Home > Our Doctors > Our Doctors > Department of Cardiology > Associate Professor Mark Chan

Associate Professor Mark Chan


MBBS (S'pore), MHS (USA), MMED (Int Med), MRCP (UK), PhD


Senior Consultant, Department of Cardiology, NUHCS

Associate Professor Department of Medicine, Yong Loo Lin School of Medicine, NUS


Associate Professor Mark Chan is a Senior Consultant at the National University Heart Centre, Singapore. His concurrent appointment is also an Associate Professor at the Yong Loo Lin School of Medicine, Singapore. He completed his cardiology training at the National University Hospital, Singapore in 2006.


He subsequently spent two years doing clinical-translational research at the Duke Clinical Research Institute, during which he served as a co-chief fellow, and graduated with a Master of Health Science degree from Duke University in 2008. He then spent another 18 months at the Montreal Heart Institute doing a combined fellowship in interventional cardiology and platelet biology.


He has authored or co-authored more than 70 papers in peer reviewed journals and is the principle investigator of multiple large outcomes studies in acute coronary syndrome, the co-principal investigator of 2 phase one studies on a novel factor IX aptamer-antidote anticoagulant system. He is an editorial board member of the American Heart Journal and deputy editor of the Asean Heart Journal.


He supervises acute coronary syndrome and thrombosis research at the Cardiovascular Research Institute (CVRI) and the high-risk acute coronary syndrome clinic at the National University Heart Centre, Singapore.


Specialty Interests:


  • Interventional Cardiology
  • Platelet biology and pharmacology
  • Metabolomics
  • Risk stratification and outcomes in Acute Coronary Syndromes


Specializes in Diseases and Conditions:


  • Antiplatelet resistance
  • Stent thrombosis
  • High risk post-STEMI patients
  • Patients with elevated peri-procedural bleeding risk


Research Interests:


  • Acute Coronary Syndromes
  • Coagulation testing
  • Anticoagulant drug discovery
  • Antithrombotic drug trials


Recent Awards (Scientific Awards):


  • Japan Society of Thrombosis and Haemostasis Asian-Pacific Scholarship 2011 for presentation entitled “Differential Prevalence and Pharmacodynamic Significance of CYP2C19 Polymorphisms in a Multiethnic Asian Cohort”
  • National Medical Research Council Clinician Scientist Award 2011


Ongoing Research Protocols:  


Stratifying risk with Metabolomics and platelet Reactivity Testing in Acute Coronary Syndromes (SMART-ACS) study funded by NMRC (Singapore). In this multinational study to profile metabolomic signatures and platelet reactivity in patients with ACS, we established a industry-academic partnership with Roche Diagnostics to test the Multiplate® system in Asian patients as part of SMART-ACS and another independent industry-commissioned study of platelet reactivity testing in healthy volunteers, and also established with SMART-ACS network in Singapore, Malaysia, Hong Kong, New Zealand and Brazil with the CVRI, Singapore as the coordinating centre.


Selected Publications (Out of 55 Peer-reviewed publications):


  1. A Phase 1b Randomized Study of Antidote-Controlled Modulation of Factor IXa Activity in Patients with Stable Coronary Artery Disease. Chan MY, Cohen MG, Dyke CK, Myles SK, Aberle LG, Lin M, Walder J, Steinhubl SR, Gilchrist IC, Kleiman NS, Vorchheimer DA, Chronos N, Melloni C, Alexander JH, Harrington RA, Tonkens RM, Becker RC, Rusconi CP. Circulation. 2008 Jun 3;117(22):2865-74.
  2. A randomized, repeat dose, pharmacodynamic, and safety study of an antidote- controlled factor IXa inhibitor. Chan MY, Rusconi CP, Alexander JH, Tonkens RM, Harrington RA, Becker RC.J Thromb Haemost. 2008 May;6(5):789-96.
  3. Long-Term Mortality of Patients Undergoing Cardiac Catheterization for ST- elevation and Non ST-elevation Myocardial Infarction. Chan MY, Sun JL, Newby LK, Shaw LK, Lin M, Peterson ED, Califf RM, Kong DF, Roe MT.Circulation. 2009 Jun 23;119(24):3110-7.
  4. Hypercoagulable States in Cardiovascular Disease. Circulation 2008 Nov 25;118(22):2286-97. Chan MY, Andreotti F, Becker RC. (Impact factor 14.816)
  5. Catheter thrombosis and percutaneous coronary intervention: fundamental perspectives on blood, artificial surfaces and antithrombotic drugs. Chan MY, Weitz JI, Merhi Y, Harrington RA, Becker RC. J Thromb Thrombolysis. 2009 Oct;28(3):366-80. (impact factor 1.846)
  6. An anti-von Willebrand factor aptamer reduces platelet adhesion among patients receiving aspirin and clopidogrel in an ex vivo shear-induced arterial thrombosis. Arzamendi D, Dandachli F, Théorêt JF, Ducrocq G, Chan M, Mourad W, Gilbert JC, Schaub RG, Tanguay JF, Merhi Y. Clin Appl Thromb Hemost. 2011 Nov-Dec;17(6):E70-8. (impactfactor 1.471)
  7. Effect on Bleeding, Time to Revascularization, and One-Year Clinical Outcomes of the Radial Approach During Primary Percutaneous Coronary Intervention in Patients With ST-Segment Elevation Myocardial Infarction. Arzamendi D, Ly HQ, Tanguay JF, Chan MY, Chevallereau P, Gallo R, Ibrahim R, L'Allier P, Levesque S, Gosselin G, Deguise P, Joyal M, Gregoire J, Bonan R, Crepeau J, Doucet S. Am J Cardiol 2010:106; 148-154 (impact factor 3. 575)
  8. REG-1, a regimen comprising RB-006, a Factor IXa antagonist, and its oligonucleotide active control agent RB-007 for the potential treatment of arterial thrombosis.Becker RC, Chan MY. Curr Opin Mol Ther. 2009 Dec;11(6):707-15. (Impact factor 3.45)
  9. First clinical application of an actively reversible direct factor IXa inhibitor as an anticoagulation strategy in patients undergoing percutaneous coronary intervention. Cohen MG, Purdy DA, Rossi JS, Grinfeld LR, Myles SK, Aberle LH, Greenbaum AB, Fry E, Chan MY, Tonkens RM, Zelenkofske S, Alexander JH, Harrington RA, Rusconi CP, Becker RC. Circulation. 2010 Aug 10;122(6):614-22. (impactfactor 14.595)
  10. Plasma Proteomics of Patients with Non-valvular Atrial Fibrillation on Chronic Anti-coagulation with Warfarin or a Direct Factor Xa Inhibitor. Chan MY, Lin M, Lucas J, Moseley A, Thompson JW, Cyr D, Ueda H, Kajikawa M, Ortel TL, Becker RC. Thromb Haemost. 2012 Dec;108(6):1180-91. (Impact factor 5.011)
  11. Catheter thrombosis and percutaneous coronary intervention: fundamental perspectives on blood, artificial surfaces and antithrombotic drugs. Chan MY, Weitz JI, Merhi Y, Harrington RA, Becker RC. J Thromb Thrombolysis. 2009 Oct;28(3):366-80. (impact factor 1.846)


For more publications, click here.


 Back to Top